AVB-S6-500 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 1 |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04042623 (ClinicalTrials.gov) | November 27, 2019 | 31/7/2019 | Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy | An Open-Label Phase 2a Study to Evaluate the Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy | IgA Nephropathy | Drug: AVB-S6-500 | Aravive, Inc. | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 2 | United States |